

# 学位論文審査結果の要旨

|  |  |     |                                    |
|--|--|-----|------------------------------------|
| 所 属  | 乙 三重大学大学院医学系研究科<br>生命医科学専攻 臨床医学系講座<br>産科婦人科学分野 | 氏 名 | 平田 <sup>ひらた</sup> 徹 <sup>とおる</sup> |
| 審 査 委 員  | 主 査 渡 邊 昌 俊<br>副 査 井 上 貴 博<br>副 査 水 野 修 吾      |     |                                    |
| <p>(学位論文審査結果の要旨)</p> <p>Safety and efficacy of levonorgestrel-releasing intrauterine device in the treatment of atypical endometrial hyperplasia and early endometrial cancer</p> <p>【主論文審査結果の要旨】</p> <p>著者らは論文において下記の内容を述べている。</p> <p>Aim: To investigate the recurrence rate, live-birth rate, and treatment outcomes of levonorgestrel-releasing intrauterine device (LNG-IUD) for the management of atypical endometrial hyperplasia (AEH) or Grade-1 endometrial cancer (EC) in patients who desire fertility-sparing treatment and those seeking conservative treatment without fertility preservation.</p> <p>Methods: We prospectively enrolled nine patients from a single institution between April 2009 and September 2013 who were followed up for 60 months after LNG-IUD insertion.</p> <p>Results: The median patient age was 35 (range: 29–39) years. The overall recurrence rate was 56% (5/9). The median interval between removal of the LNG-IUD and recurrence was 20.5 (range: 2–30) months. Three of the nine patients had Grade-1 EC, and six had AEH. The response rates to the LNG-IUD in patients with Grade-1 EC and AEH were 66% and 100%, respectively. Four patients (three with AEH, one with Grade-1 EC) experienced recurrence 6 months after MPA treatment and all 4 (100%) had complete response. Eight patients desired fertility preservation, of which 37% (3/8) conceived after</p> |  |     |                                    |

receiving fertility treatment and 25% (2/8) had a live birth; the remaining three had previously received MPA for 6 months and had a recurrence; of these, 1 had a live birth. Conclusion: LNG-IUD is effective for the management of AEH and EC in young patients who desire fertility-sparing treatment, including those ineligible for MPA owing to the presence of comorbidities and those with recurrence after MPA treatment (6-month treatment), and patients seeking conservative treatment without fertility preservation.

子宮体癌および子宮内膜異型増殖症患者におけるレボノルゲストレル放出子宮内器具による妊孕性温存療法について、その治療効果と安全性について報告した本邦では数少なく、かつ非常に長い期間観察した論文であり、学術上極めて有益であり、学位論文として価値あるものと認めた。

THE JOURNAL OF Obstetrics and Gynaecology Research

Published: 2022 August 29

doi: 10.1111/jog.15408

Toru Hirata, Eiji Kondo, Shoichi Magawa, Michiko Kubo-Kaneda,  
Masafumi Nii, Kenta Yoshida, Tadashi Maezawa, Tsutomu Tabata and  
Tomoaki Ikeda